RNA · Atrium Therapeutics, Inc.
$13.20
-0.28 (-2.08%)
At close · Aug 21
Market Cap
$225.79M
Shares
17.11M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Simona Skerjanec | director | Appointed | 2026-02-27 |
| Troy Wilson | director | Appointed | 2026-02-27 |
| W. Michael Flanagan | director | Appointed | 2026-02-27 |
| Carsten Boess | director | Appointed | 2026-02-27 |
Key facts
CIK
2093101
CUSIP
04965N104
13F (30d)
149 filings
146 filers
Visit website
Investor relations